Primary Biliary Cholangitis Supportive Care Protocol
Primary Stack
Core supplements with strongest evidenceCommonly deficient due to fat malabsorption; critical for bone health (osteoporosis risk high in PBC)
Supporting Studies (1)
Important for bone health; may be poorly absorbed; osteoporosis prevention
Supporting Studies (1)
Supporting Stack
Additional supplements for enhanced resultsFat-soluble vitamin often deficient in PBC; supports vision and immune function
Supporting Studies (1)
Fat-soluble vitamin deficiency common; antioxidant; may help with neuropathy
Supporting Studies (1)
Often deficient; essential for coagulation; may need monitoring
Supporting Studies (1)
Anti-inflammatory; may help with hypertriglyceridemia common in PBC
Supporting Studies (1)
Supports liver methylation and glutathione; some evidence in cholestatic liver disease
Supporting Studies (1)
Traditional hepatoprotective herb; antioxidant; limited evidence in PBC specifically
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Primary Biliary Cholangitis (PBC), formerly called Primary Biliary Cirrhosis, is an autoimmune disease where the body's immune system attacks the small bile ducts in the liver. This leads to bile buildup, which damages the liver over time.
KEY FEATURES:
COMMON SYMPTOMS:
CRITICAL: PBC requires medical treatment with ursodeoxycholic acid (UDCA) - this is the cornerstone therapy. This protocol is SUPPORTIVE ONLY.
STANDARD TREATMENT:
ASSOCIATED CONDITIONS:
* Vitamin D and Calcium are critical for bone health.
* Fat-soluble vitamins (A, D, E, K) often need supplementation.
* Monitor bone density regularly and treat osteoporosis if present.
Expected timeline: PBC is a chronic disease. UDCA can significantly slow progression. Life expectancy normal or near-normal with early treatment and good response.
Clinical Perspective
Primary Biliary Cholangitis: Autoimmune cholangiopathy with granulomatous destruction of interlobular bile ducts. Female predominance 9:1. Diagnosis: elevated ALP, positive AMA (95%), liver biopsy for staging if needed. Natural history: variable; progresses to cirrhosis without treatment. UDCA response: ~60% have adequate biochemical response; determines prognosis.
CRITICAL: UDCA is cornerstone treatment - 13-15mg/kg/day. Inadequate responders: add obeticholic acid or fibrate. Monitor for complications: osteoporosis (30-40%), fat-soluble vitamin deficiencies, varices if cirrhotic. Pruritus management: cholestyramine first-line, rifampin, naltrexone, sertraline. Fatigue: most disabling symptom; no effective treatment. Supplements address nutritional deficiencies from cholestasis - fat-soluble vitamins essential.
* Vitamin D (A-grade): Malabsorption; osteoporosis. Systematic review: (PMID: 28750270). 2000-4000 IU daily. Higher if deficient.
* Calcium (A-grade): Bone health. Guidelines: (PMID: 28332116). 1000-1200mg daily.
* Vitamin A (B-grade): Fat-soluble. Review: (PMID: 27450775). 10,000-25,000 IU daily. Monitor levels.
* Vitamin E (B-grade): Fat-soluble. Review: (PMID: 23075608). 400-800 IU daily. Water-soluble form if needed.
* Vitamin K (B-grade): Coagulation. Review: (PMID: 27450775). 2.5-10mg daily or PRN.
* Omega-3 (C-grade): Anti-inflammatory. Systematic review: (PMID: 27840029). 2-3g EPA+DHA daily.
* SAMe (C-grade): Liver support. Cochrane: (PMID: 25758370). 800-1600mg daily.
* Milk Thistle (C-grade): Hepatoprotective. Cochrane: (PMID: 22059891). 420-600mg silymarin daily.
Assessment targets: ALP, bilirubin, albumin, liver function, vitamin levels, bone density, pruritus severity, fatigue.
Protocol notes: Osteoporosis: high prevalence; DEXA every 2-3 years; bisphosphonates if osteoporotic (caution with esophageal varices). Fat-soluble vitamins: check levels; malabsorption increases with cholestasis severity. Pruritus: very distressing; cholestyramine (separate from other meds by 4 hours); rifampin if refractory; phototherapy sometimes helps. Fatigue: no effective treatment; rule out hypothyroidism, anemia, depression. Sicca: artificial tears, saliva substitutes. Varices: screen if cirrhotic; prophylaxis if indicated. Transplant: excellent outcomes; ~90% 1-year survival; recurrence in graft can occur. Pregnancy: UDCA safe in pregnancy. AMA-negative PBC: ~5%; treat same way. Overlap syndromes: AIH-PBC overlap exists; may need immunosuppression. Monitoring: regular LFTs, annual fat-soluble vitamin levels, periodic DEXA.